A drug maker focused on development and commercialization of diabetes treatments unveiled its accelerating clinical development plans of two drug candidates.
Perrigo on Thursday announced that it has entered into an exclusive agreement with AgaMatrix to sell and distribute blood-glucose monitors and test strips in the U.S. store-brand channel.
Individuals who have higher blood-glucose levels and poorer control of those levels over time appear more likely to develop eye-related complications 10 years later, according to a report in the February issue of Archives of Ophthalmology published Monday.
Danish drug maker Novo Nordisk has created an online resource for diabetes patients that educates them about Novo Nordisk drugs and devices, recipes and nutritional values, and allows them to connect with other patients.
Community-based healthcare models, and the nurse practitioners who work within them, are particularly helpful in assisting diabetes patients with such underlying health conditions as depression, according to a recent study published on Nurse.com.
A recent scientific study showed that incorporating almonds into a person’s diet can help treat and possibly prevent Type 2 diabetes, as well as cardiovascular disease, the Almond Board of California announced Wednesday.
Supplier News — Fera Pharmaceuticals has recently launched two new topical ointments. The New York-based company has developed Ilotycin (erythromycin) and Garamycin (gentamicin) ophthalmic ointments, both for the treatment of bacterial infections of the eye. “Our goal is simple: to keep more quality healthcare choices alive for the people who need them,” company co-founder Frank DellaFera said.
Walgreens' chief medical officer will discuss the evidence-based medicine design and impact of a diabetes management program delivered by pharmacists at both workplace and community pharmacies during an upcoming conference, the drug store chain said.
The Journal of the American Dietetic Association has published a list of nutritional practice guidelines for people with Type 1 and Type 2 diabetes in its December issue.